Ibogaine Research Database

692 research records indexed from PubMed. Plain-language summaries where available.

Of these, 52 are human clinical studies (trials, observational studies, or case reports), 398 are preclinical (animal or lab) studies, and 112 are reviews or meta-analyses summarizing other researchers’ data. A record appearing here does not by itself mean ibogaine is proven effective for a given condition — see each condition page’s evidence breakdown for what’s actually established.

Compare evidence by condition →

All Studies (692)Depression (56)PTSD (24)Alcohol Addiction (20)Heroin Addiction (16)Opioid Addiction (15)Cocaine Addiction (15)Anxiety (13)Methamphetamine Addiction (12)Traumatic Brain Injury (2)

All Studies(692 of 692)

Further investigations of the serotonergic properties of the ibogaine-induced discriminative stimulus.

Helsley, Rabin, Winter· Prog Neuropsychopharmacol Biol Psychiatry· 1999· PMID: 10368872
Preclinical (Animal)

1. 5-HT3, 5-HT2C, and 5-HT1A receptor ligands were assessed in rats trained to discriminate ibogaine from water. 2. Significant ibogaine-appropriate responding was observed following treatment with the 5-HT2C agonists MK-212 (79.6%) and mCPP (76.4%). This substitution was complet...

Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine.

Fryer, Lukas· J Pharmacol Exp Ther· 1999· PMID: 9862757
Unclassified

Nicotinic acetylcholine receptors (nAChR) are diverse members of the neurotransmitter-gated ion channel superfamily and play critical roles in chemical signaling throughout the nervous system. The present study establishes the acute functional effects of bupropion, phencyclidine,...

Acute ibogaine injection induces expression of the immediate early genes, egr-1 and c-fos, in mouse brain.

Ali, Thiriet, Zwiller· Brain Res Mol Brain Res· 1999· PMID: 10640697
Preclinical (Animal)

The aim of the present study was to evaluate if an acute injection of ibogaine (IBO) induces immediate early gene expression in different regions of mouse brain. Adult male C57 mice received a single injection of IBO and were perfused transcardially with 1% paraformaldehyde 30 mi...

Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain.

Zubaran, Shoaib, Stolerman et al.· Neuropsychopharmacology· 1999· PMID: 10379526
Preclinical (Animal)

The discriminative stimulus effects of ibogaine and noribogaine in rats have been examined in relation to their concentrations in blood plasma and brain regions and to receptor systems through which they have been proposed to act. Rats were trained to discriminate ibogaine (10 mg...

Ibogaine enhances the expression of locomotor sensitization in rats chronically treated with cocaine.

Szumlinski, Maisonneuve, Glick· Pharmacol Biochem Behav· 1999· PMID: 10418788
Preclinical (Animal)

Pretreatment (19 h) with the putative antiaddictive agent, ibogaine, has been shown previously to potentiate cocaine-induced locomotion in rats. The present study demonstrates that the magnitude of this effect of ibogaine is dependent on the previous cocaine history of the animal...

The effects of ibogaine on dopamine and serotonin transport in rat brain synaptosomes.

Wells, Lopez, Tanaka· Brain Res Bull· 1999· PMID: 10386845
Preclinical (Animal)

Ibogaine has been shown to affect biogenic amine levels in selected brain regions. Because of the involvement of these neurotransmitters in drug addiction, the effects of ibogaine on biogenic amine transport may contribute to the potential anti-addictive properties of ibogaine in...

Ibogaine blocked methamphetamine-induced hyperthermia and induction of heat shock protein in mice.

Yu, Imam, Newport· Brain research· 1999· PMID: 10095030
Preclinical (Animal)

Body temperature changes and heat shock protein (HSP-72) induction in the caudate nucleus were studied in female C57BL/6N mice pretreated with ibogaine (50 mg/kg) and sacrificed 48 h. after a single dose of methamphetamine (20 mg/kg). Methamphetamine injection resulted in hyperth...

Pretreatment with the putative anti-addictive drug, ibogaine, increases the potency of cocaine to elicit locomotor responding: a study with acute and chronic cocaine-treated rats.

Szumlinski, Maisonneuve, Glick· Psychopharmacology· 1999· PMID: 10463325
Preclinical (Animal)

Results of single-dose studies suggest that the effects of pretreatment with the putative anti-addictive compound, ibogaine, on drug-induced locomotor behavior depends on the previous drug history of the animal. To compare the effects of ibogaine pretreatment on the dose-locomoto...

Differential responses by neurotensin systems in extrapyramidal and limbic structures to ibogaine and cocaine.

Alburges, Hanson· Brain research· 1999· PMID: 9914442
Preclinical (Animal)

Ibogaine (Endabuse) is a psychoactive indole alkaloid found in the West African shrub, Tabernanthe iboga. This drug interrupts cocaine and amphetamine abuse and has been proposed for treatment of addiction to these stimulants. However, the mechanism of action that explains its ph...

Ibogaine pretreatment dramatically enhances the dynorphin response to cocaine.

Alburges, Hanson· Brain research· 1999· PMID: 10564747
Preclinical (Animal)

Ibogaine (Endabuse) is a psychoactive indole alkaloid found in the shrub, Tabernanthe iboga, which has been used to treat stimulant addiction. Because ibogaine influences the activity of neurotensin systems, a dopamine-linked neuropeptide, the present study investigated if ibogai...

Treatment of acute opioid withdrawal with ibogaine.

Alper, Lotsof, Frenken· The American journal on addictions· 1999· PMID: 10506904
Clinical Trial

Ibogaine is an alkaloid with putative effect in acute opioid withdrawal. Thirty-three cases of treatments for the indication of opioid detoxification performed in non-medical settings under open label conditions are summarized involving an average daily use of heroin of .64 +/- ....

Neurochemical and Neuroendocrine Effects of Ibogaine in Rats: Comparison to MK-801.

Baumann, Rothman, Ali· Ann N Y Acad Sci· 1998· PMID: 29090818
Preclinical (Lab)

Ibogaine (IBO) is a naturally-occurring indole compound that is being evaluated as a potential medication for substance use disorders. Although the precise mechanism of IBO action is unclear, recent in vitro data show this drug displays properties similar to the noncompetitive N-...

Determination of common drugs of abuse in body fluids using one isolation procedure and liquid chromatography--atmospheric-pressure chemical-ionization mass spectromery.

Bogusz, Maier, Krüger et al.· J Anal Toxicol· 1998· PMID: 9847004
Preclinical (Lab)

A method for determining opiate agonists (morphine, morphine-3-glucuronide, morphine-6-glucuronide, 6-monoacetylmorphine, codeine, codeine-6-glucuronide, dihydrocodeine, dihydromorphine, buprenorphine, methadone, tramadol, and ibogaine), cocaine and its metabolites (benzoylecgoni...

Alteration in Electroencephalogram and Monoamine Concentrations in Rat Brain following Ibogaine Treatment.

Binienda, Beaudoin, Thorn et al.· Ann N Y Acad Sci· 1998· PMID: 29090814
Preclinical (Lab)

Ibogaine (IBO) is a psychoactive indole alkaloid that has antiaddictive properties. However, treatment with IBO may lead to neurotoxicity, since IBO and its metabolites interact persistently with many neurotransmitter systems. Here, we recorded cortical electroencephalogram (EEG)...

Annals of the New York Academy of Sciences

Itzhak, Ali· Ann N Y Acad Sci· 1998· PMID: 29090808
Preclinical (Lab)

Although the alkaloid ibogaine is a potent hallucinogenic agent some indications suggest that it may be useful for the treatment of opioid and cocaine addiction. The neurochemical mechanism(s) underlying ibogaine effects remain unclear. In the present study we investigated the in...

Annals of the New York Academy of Sciences

Glick, Maisonneuve· Ann N Y Acad Sci· 1998· PMID: 29090809
Preclinical (Lab)

Ibogaine, an alkaloid extracted from Tabemanthe iboga, is being studied as a potential long-acting treatment for oploid and stimulant abuse as well as for alcoholism and smoking. Studies in this laboratory have used animal models to characterize ibogaine's interactions with drugs...

Gender differences in kappa-opioid modulation of cocaine-induced behavior and NMDA-evoked dopamine release.

Sershen, Hashim, Lajtha· Brain Res· 1998· PMID: 9729284
Preclinical (Animal)

It has been reported that kappa-opioids produce greater analgesia in women than in men. Sex differences are also apparent in drug-induced behaviors. Repeated administration of cocaine (25 mg/kg) produced a greater locomotor and sensitization response in C57BL/6By female mice. It ...

Modulation of the neuronal response to N-methyl-D-aspartate by selective sigma2 ligands.

Couture, Debonnel· Synapse· 1998· PMID: 9552175
Preclinical (Animal)

It has now been accepted for several years that sigma (sigma) receptors exist in, at least, two distinct entities denoted sigma1 and sigma2. Previous electrophysiological studies from our laboratory have demonstrated that several selective sigma1 ligands potentiate the neuronal r...

Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats.

Rho, Glick· Neuroreport· 1998· PMID: 9631413
Preclinical (Animal)

Ibogaine, an alkaloid found in the root bark of the African shrub Tabernanthe iboga, has been claimed to interrupt opioid dependence in humans; in animals, it has been shown to inhibit morphine self-administration and to attenuate signs of morphine withdrawal. However, ibogaine h...

Antimycobacterial activity of chemically defined natural substances from the Caribbean flora in Guadeloupe.

Rastogi, Abaul, Goh et al.· FEMS Immunol Med Microbiol· 1998· PMID: 9626931
Unclassified

Eight chemically defined, naturally occurring compounds were extracted from the tropical flora of the Caribbean island of Guadeloupe: pilocarpine, an alkaloid from Pilocarpus racemosus; heraclenol and isomeranzin, coumarins from Triphasia trifolia; lochnerin, an indole alkaloid f...

Fight to develop drug addiction therapy.

Birmingham· Nat Med· 1998· PMID: 9546770
Unclassified

Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats.

Wei, Maisonneuve, Kuehne et al.· Brain Res· 1998· PMID: 9685673
Preclinical (Animal)

The iboga alkaloid, ibogaine, its metabolite, noribogaine, and the congener, 18-methoxycoronaridine (18-MC) have all been claimed to have anti-addictive properties in animal models, but the mechanisms underlying these effects are unclear. Ibogaine and noribogaine were shown to ha...

18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats.

Glick, Maisonneuve, Visker et al.· Psychopharmacology (Berl)· 1998· PMID: 9784085
Preclinical (Animal)

Two studies were conducted to assess, in vivo, potential anti-nicotinic effects of the iboga alkaloid ibogaine and its synthetic congener 18-methoxycoronaridine (18-MC). As previously demonstrated for ibogaine, using microdialysis, pretreatment (19h beforehand) with 18-MC (40 mg/...

The Neurochemistry of Drugs of Abuse: Cocaine, Ibogaine, and Substituted Amphetamines. Proceedings of a meeting. Hamilton, Bermuda, July 16-18, 1997.

· Ann N Y Acad Sci· 1998· PMID: 9705733
Preclinical (Animal)

Alteration of electroencephalogram and monoamine concentrations in rat brain following ibogaine treatment.

Binienda, Beaudoin, Thorn et al.· Ann N Y Acad Sci· 1998· PMID: 9668684
Preclinical (Animal)

Ibogaine (IBO) is a psychoactive indole alkaloid that has antiaddictive properties. However, treatment with IBO may lead to neurotoxicity, since IBO and its metabolites interact persistently with many neurotransmitter systems. Here, we recorded cortical electroencephalogram (EEG)...

The effects of beta-carbolines in rats trained with ibogaine as a discriminative stimulus.

Helsley, Rabin, Winter· Eur J Pharmacol· 1998· PMID: 9600629
Preclinical (Animal)

The structural features and hallucinogenic properties shared by ibogaine and certain beta-carbolines prompted the evaluation of several representative beta-carbolines in rats trained with ibogaine as a discriminative stimulus. In a previous report from our laboratory harmaline co...

Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice.

Sunder Sharma, Bhargava· Pharmacology· 1998· PMID: 9742287
Preclinical (Animal)

The effects of ibogaine, an alkaloid isolated form the bark of the African shrub, Tabernathe iboga, and noribogaine, a metabolite of ibogaine, on morphine antinociception were determined in male Swiss-Webster mice. Mice were rendered tolerant to morphine by implanting them with a...

Annals of the New York Academy of Sciences

Onaivi, Ali, Chakrabarti· Ann N Y Acad Sci· 1998· PMID: 29090806
Preclinical (Lab)

Ibogaine may have antiaddiction potential against alcohol, psychostimulant and opiate abuse, but its mechanism of action is unclear. Ibogaine, however, has been demonstrated in numerous studies to have effects in multiple central nervous system (CNS) neurotransmitters systems. We...

Neurochemical and neuroendocrine effects of ibogaine in rats: comparison to MK-801.

Baumann, Rothman, Ali· Ann N Y Acad Sci· 1998· PMID: 9668683
Preclinical (Animal)

Ibogaine (IBO) is a naturally-occurring indole compound that is being evaluated as a potential medication for substance use disorders. Although the precise mechanism of IBO action is unclear, recent in vitro data show this drug displays properties similar to the noncompetitive N-...

Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys.

Jones, Li, Balster· Pharmacol Biochem Behav· 1998· PMID: 9476989
Preclinical (Animal)

The discriminative stimulus properties of ibogaine were investigated in rats trained to discriminate phencyclidine (PCP; 2.0 mg/kg, I.P.) from saline under a two-lever fixed-ratio (FR) 32 schedule of food reinforcement. Ibogaine (5.6-17.6 mg/kg, I.P.) showed a complete lack of su...

Noribogaine stimulates naloxone-sensitive [35S]GTPgammaS binding.

Pablo, Mash· Neuroreport· 1998· PMID: 9592058
Preclinical (Animal)

Noribogaine is formed in vivo by the O-demethylation of the indole alkaloid ibogaine. We report here that noribogaine acts as a full agonist at the mu-opioid receptor. Noribogaine-stimulated guanylyl 5'gamma-[35S]thio]triphosphate ([35S]GTPgammaS) was studied in rat thalamic memb...

Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.

Efange, Mash, Khare et al.· J Med Chem· 1998· PMID: 9804688
Preclinical (Animal)

Five phenyl-substituted derivatives and analogues of 1,2,3,4,5, 6-hexahydroazepino[4,5-b]indole, 5, a major fragment of ibogaine (1), were synthesized and tested for binding to monoamine transporters, the NMDA receptor-coupled cation channel, and dopamine and opioid receptors. Al...

Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine.

Obach, Pablo, Mash· Drug Metab Dispos· 1998· PMID: 9698290
Unclassified

Ibogaine is a psychoactive alkaloid that possesses potential as an agent to treat opiate and cocaine addiction. The primary metabolite arises via O-demethylation at the 12-position to yield 12-hydroxyibogamine. In this report, evidence is presented that the O-demethylation of ibo...

Behavioral and biochemical evidence for a nonessential 5-HT2A component of the ibogaine-induced discriminative stimulus.

Helsley, Fiorella, Rabin et al.· Pharmacol Biochem Behav· 1998· PMID: 9476990
Preclinical (Animal)

In the present investigation, the ability of two known hallucinogens, lysergic acid dimethylamide (LSD) and (-)-2,5-dimethoxy-4-methyl-amphetamine (DOM), to substitute for the ibogaine-induced discriminative stimulus (10 mg/kg I.P., 60 min presession) was assessed in Fischer-344 ...

The effects of sigma, PCP, and opiate receptor ligands in rats trained with ibogaine as a discriminative stimulus.

Helsley, Filipink, Bowen et al.· Pharmacol Biochem Behav· 1998· PMID: 9477000
Preclinical (Animal)

Although the mechanism of action of ibogaine, a hallucinogen that may be useful in the treatment of addiction, remains unknown, receptor binding studies suggest that ibogaine produces its effects via interactions with multiple receptor types. In addition to serotonergic receptors...

Effect of ibogaine on the various sites of the NMDA receptor complex and sigma binding sites in rat brain.

Itzhak, Ali· Ann N Y Acad Sci· 1998· PMID: 9668682
Preclinical (Animal)

Although the alkaloid ibogaine is a potent hallucinogenic agent some indications suggest that it may be useful for the treatment of opioid and cocaine addiction. The neurochemical mechanism(s) underlying ibogaine effects remain unclear. In the present study we investigated the in...

Annals of the New York Academy of Sciences

Mash, Kovera, Buck et al.· Ann N Y Acad Sci· 1998· PMID: 29090804
Preclinical (Lab)

The potential for deriving new psychotherapeutic medications from natural sources has led to renewed interest in rain forest plants as a source of lead compounds for the development of antiaddiction medications. Ibogaine is an indole alkaloid found in the roots of Tabernanthe ibo...

Observations on treatment with ibogaine.

Luciano· Am J Addict· 1998· PMID: 9522011
Clinical Trial

Ibogaine acts at the nicotinic acetylcholine receptor to inhibit catecholamine release.

Mah, Tang, Liauw et al.· Brain Res· 1998· PMID: 9630615
Preclinical (Animal)

In an effort to determine mechanisms of action of the putative anti-addictive agent ibogaine, we have measured its effects on catecholamine release in a model neuronal system, cultured bovine chromaffin cells. Various modes of stimulating catecholamine release were used including...

Medication development of ibogaine as a pharmacotherapy for drug dependence.

Mash, Kovera, Buck et al.· Ann N Y Acad Sci· 1998· PMID: 9668685
Review

The potential for deriving new psychotherapeutic medications from natural sources has led to renewal interest in rain forest plants as a source of lead compounds for the development of antiaddiction medications. Ibogaine is an indole alkaloid found in the roots of Tabernanthe ibo...

In vivo ibogaine blockade and in vitro PKC action of cocaine.

Onaivi, Ali, Chakrabarti· Ann N Y Acad Sci· 1998· PMID: 9668681
Review

Ibogaine may have antiaddiction potential against alcohol, psychostimulant and opiate abuse, but its mechanism of action is unclear. Ibogaine, however, has been demonstrated in numerous studies to have effects in multiple central nervous system (CNS) neurotransmitters systems. We...

Seeking ways to crack cocaine addiction.

Morris· Lancet (London, England)· 1998· PMID: 9788471
Unclassified

Mechanisms of antiaddictive actions of ibogaine.

Glick, Maisonneuve· Annals of the New York Academy of Sciences· 1998· PMID: 9668680
Review

Ibogaine, an alkaloid extracted from Tabemanthe iboga, is being studied as a potential long-acting treatment for oploid and stimulant abuse as well as for alcoholism and smoking. Studies in this laboratory have used animal models to characterize ibogaine's interactions with drugs...

Selective damage to the cerebellar vermis in chronic alcoholism: a contribution from neurotoxicology to an old problem of selective vulnerability.

Cavanagh, Holton, Nolan· Neuropathol Appl Neurobiol· 1997· PMID: 9364460
Review

The curiously consistent localization of cerebellar cortical damage in chronic alcoholism is re-evaluated in the light of selective damage, with a similar topography in the cerebellar vermal region, in superficial siderosis in man and in experimental animals exposed to certain to...

Serotonergic mediation of fenfluramine discriminative stimuli in fawn-hooded rats.

Schechter· Life Sci· 1997· PMID: 9031690
Preclinical (Animal)

Fenfluramine, a drug that induces increased synaptic serotonin, was used to train Fawn-Hooded rats in a drug discrimination paradigm. This strain of rats is thought to possess a genetic serotonin storage abnormality. The intent of the study was to see if the Fawn-Hooded rat was s...

Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration.

Schmued, Albertson, Slikker· Brain Res· 1997· PMID: 9098566
Preclinical (Animal)

Fluoro-Jade is an anionic fluorochrome capable of selectively staining degenerating neurons in brain slices. The histochemical application of Fluoro-Jade results in a simple, sensitive and reliable method for staining degenerating neurons and their processes. The technique will d...

Effects of noribogaine on the development of tolerance to antinociceptive action of morphine in mice.

Bhargava, Cao· Brain Res· 1997· PMID: 9401754
Preclinical (Animal)

The effects of noribogaine, a metabolite of ibogaine, on the development of tolerance to the antinociception action of morphine was determined in male Swiss-Webster mice. Ibogaine is an alkaloid isolated from the bark of the African shrub, Tabernanthe iboga. Morphine tolerance in...

Time-dependent interactions between iboga agents and cocaine.

Maisonneuve, Visker, Mann et al.· Eur J Pharmacol· 1997· PMID: 9384223
Preclinical (Animal)

The purpose of this study was to clarify the effects of iboga agents on cocaine-induced hyperactivity. Both inhibition and enhancement of cocaine-induced activity by ibogaine have been reported. In the present study, rats were treated with either ibogaine (40 mg/kg, i.p.), noribo...

Effects of chronic ibogaine treatment on cerebellar Purkinje cells in the rat.

Helsley, Dlugos, Pentney et al.· Brain Res· 1997· PMID: 9221953
Preclinical (Animal)

The present investigation assessed the chronic toxicity of ibogaine on cerebellar Purkinje cells in male Fischer 344 rats. A behaviorally active dose of ibogaine (10 mg/kg, i.p.) was administered to a group of six subjects every other day for 60 days while the control group recei...

The effects of noribogaine and harmaline in rats trained with ibogaine as a discriminative stimulus.

Helsley, Rabin, Winter· Life Sci· 1997· PMID: 9048970
Preclinical (Animal)

In the present investigation, Fischer-344 rats were trained to discriminate 10.0 mg/kg of ibogaine from water using a pretreatment time of 60 minutes. Analysis of dose response data generated an ED50 of 4.6 mg/kg. The time course of the ibogaine (10.0 mg/kg) cue was also determin...

← PrevPage 11 / 14Next →